Authorization

Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the a??Companya?? or a??Bioasisa??), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 a?? platform technology for the delivery of therapeutics across the blood-brain barrier (a??BBBa??) and the treatment of central nervous system (a??CNSa??) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that John D. Vandermosten, CFA, Biotechnology Analyst of Zacks Small Cap Research division at Zacks Investment Research and his team (a??Zacksa??) has initiated analyst coverage on Bioasis Technologies Inc.
A copy of the research report may be obtained directly from the analyst at Zacks by contacting Mr. Vandermosten, on +1.312.265.9588 or at jvandermosten@zacks.com or by contacting the Zacks Small Cap Research team at scr@zacks.com.All reports on Bioasis prepared by analysts represent the views of such analysts and are not necessarily those of Bioasis. Bioasis is not responsible for the content, accuracy or timelines provided by analysts.On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D.
Executive Chair of the Board
deborah@bioasis.us
+1.203.533.7082Follow on:
Twitter
LinkedIn
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2020    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
30